MARK KLINE - X-THERMA

Dr. Mark Kline serves as the technical and operating lead for X-Therma Inc., a company working to improve the storage and transport of regenerative medicines, where he oversees the management of government support, among other roles. Dr. Kline has been continuously involved in research at the interplay of chemistry and biology and brings technical expertise to the ARMI BioFabUSA community in the areas of supramolecular interactions, peptidomimetic and polymer systems, and the design and characterization of supramolecular nanostructures. At X-Therma Inc., he has developed a fundamentally different research program in the cryopreservation field, focused on improving the chemistry of cryopreservation. Dr. Kline’s focus on technology and operations and his unique scientific background will be valuable as ARMI BioFabUSA continues to move toward its goal of building the future of biofabrication. At X-Therma, he has built the operations and research systems needed to move from conceptual ideas to funded research, through expansion, and into development phases as various funding opportunities were awarded to the company through the Department of Defense, National Science Foundation, and California Institute of Regenerative Medicine. As Vice Chair of Berkeley Postdoctoral Entrepreneur Program (2014-2017), he provided guidance to postdocs in their entrepreneurial endeavors at the institution level. He also served as POC on a range of multi-million-dollar international procurement projects while completing his Ph.D. study. During his postdoctoral studies at Lawrence Berkeley National Laboratory, Dr. Kline played a critical role as synthesis team lead for a Defense Advanced Research Projects Agency (DARPA) Fold F(x) project “A Synthetic Immune System based on Peptoid Nanoswatches.” This 15-member, 4 institution team made large strides in biomimetic nanoscience to detect threat agents and discover new catalysts, while dramatically improving the synthesis of peptoids over 40 residues in length from 2 weeks per peptoid to 24 peptoids in 24 hours, among other advancements.